北美甲状腺癌诊断市场，按产品类型（仪器、消耗品和配件）、测试类型（影像测试、活检、血液测试、其他）、癌症类型（乳头状癌、滤泡性癌、其他）、分期（第一期、第二期、第三期、第四期）、年龄组（21 岁以下、21-29 岁、30-65 岁、65 岁及以上）、最终用户（医院、相关实验室、独立诊断实验室、诊断影像中心、癌症研究机构等）、分销渠道（直接招标、零售销售）划分 - 行业趋势和预测到 2030 年。
北美甲状腺癌诊断市场分析与洞察
人们对甲状腺癌的认识不断提高，市场需求也随之增加。为获得更好的医疗服务而增加的医疗支出也促进了市场的增长。在这一关键时期，主要的市场参与者专注于各种服务的推出和批准。此外，诊断过程和技术的改进也促进了对甲状腺癌诊断测试的需求增加。
北美甲状腺癌诊断市场预计将在 2023 年至 2030 年的预测期内增长。Data Bridge Market Research 分析称，在 2023 年至 2030 年的预测期内，该市场以 6.4% 的复合年增长率增长，预计到 2030 年将达到 53.9106 亿美元。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (可定制至 2020-2015) |
|
定量单位 |
收入（百万美元） |
|
涵盖的领域 |
按产品类型（仪器、耗材及配件）、检测类型（影像检测、活检、血液检测、其他）、癌症类型（乳头状癌、滤泡性癌、其他）、分期（I 期、II 期、III 期、IV 期）、年龄组（21 岁以下、21-29 岁、30-65 岁、65 岁及以上）、最终用户（医院、相关实验室、独立诊断实验室、诊断影像中心、癌症研究机构等）、分销渠道（直接招标、零售） |
|
覆盖国家 |
美国、加拿大和墨西哥 |
|
涵盖的市场参与者 |
佳能公司、富士胶片控股株式会社、罗氏公司、Quest Diagnostics Incorporated、Illumina、荷兰皇家飞利浦电子公司、赛默飞世尔科技公司、西门子医疗有限公司、雅培、通用电气公司、BD、QIAGEN、DIASORIN SPA、默克集团、Hologic、Myriad Genetics Inc.、BIOMERIEUX、FONAR Corp.、美时医疗控股、PlexBio.、明方医疗系统有限公司、Medonica 有限公司、北京欧德生物技术有限公司和 SternMed GmbH. 等 |
市场定义
甲状腺癌是一种始于甲状腺的癌症。当细胞开始失控生长时，癌症就开始了。甲状腺会产生激素，帮助调节新陈代谢、心率、血压和体温。甲状腺位于颈部前部，甲状软骨（喉结）下方。大多数人看不到或摸不到甲状腺。它的形状像蝴蝶，有两个叶——右叶和左叶——由一个狭窄的腺体部分连接，称为峡部。
北美甲状腺癌诊断市场动态
司机
甲状腺结节和癌症的发病率和患病率上升
甲状腺结节是甲状腺细胞在甲状腺内异常生长（肿块）。有时正常的甲状腺软组织开始生长，导致这些结节形成。结节的发病率随着年龄的增长而增加，主要发生在女性身上，多见于碘缺乏症患者和放射线暴露后患者。虽然这些结节的进一步并发症是甲状腺癌，但甲状腺结节转变为甲状腺癌的可能性很低。根据 2017 年发表在 NCBI 上的一篇名为“4 厘米或更大的甲状腺结节的恶性肿瘤风险”的文章，结节后发生癌症的病例占总结节病例的不到 5%。此外，甲状腺结节在家族史中很常见，碘摄入量低的人群中也常见。
甲状腺癌诊断检测数量上升
甲状腺超声检查是一种通过手持式仪器拍摄的甲状腺声波图像，并在显示器上转换为二维图像。它用于诊断甲状腺肿瘤、囊肿或甲状腺肿，是一种无痛、无风险的检查。这些测试用于评估结构异常，而测量 TSH、T4 和 T3 水平的血液测试用于检查功能变量。细针活检用于可疑病例，以确定肿瘤是良性还是恶性。此外，分子检测和基因预后的引入推动了甲状腺癌诊断市场的诊断前景。
提高对甲状腺癌的认识
人们对甲状腺癌的认识不断增强，导致对及时检测癌症的需求增加，从而促进市场增长。
甲状腺癌是导致美国人口死亡率上升的主要原因之一，并将在未来五年推动市场增长。辐射暴露和甲状腺疾病家族史是甲状腺癌的主要风险因素。女性被诊断出患有甲状腺癌的人数明显高于男性。
限制
诊断费用高昂
由于甲状腺癌患者数量不断增加，医疗设备价格不断上涨，癌症诊断变得越来越昂贵。癌症诊断中使用的现代技术设备在癌症诊断的高价格和高准确性方面也发挥着重要作用，为甲状腺结节中的癌症提供明确的诊断。因此，甲状腺癌诊断程序的高成本阻碍了市场的增长。
用于检测癌症的诊断产品或设备正在变得越来越先进，但与此同时，癌症诊断程序也非常昂贵，这阻碍了甲状腺癌诊断市场的增长，因为用于癌症诊断过程的设备变得越来越昂贵，导致诊断程序成本增加。因此，癌症诊断的高成本限制了北美甲状腺癌诊断市场的发展。
影像学检查的高辐射暴露导致的组织损伤
高辐射暴露会导致严重的组织损伤，并增加一个人日后患癌症的几率。虽然重要的是要了解这种风险，但用于成像测试的微小辐射剂量可能会略微增加一个人患癌症的风险。一个人接受的辐射量因测试类型、暴露的身体部位、体型、年龄和性别等因素而异。使用辐射的成像检查应仅在必要时进行，因为来自所有来源的辐射暴露可能会在一生中累积起来，并可能增加患癌症的几率。其他成像程序（如超声波或 MRI）也可能经常使用。
机会
癌症诊断和治疗医疗支出增加
在全球范围内，由于公共卫生支出和经济表现，研发活动不断增加，而医疗保健行业在医疗保健支出方面位居所有行业第二位。医疗保健支出的增加可以带来更好的研发机会。预计这将增加对卵巢癌诊断的需求。
癌症治疗医疗支出的增加也有助于患者轻松接受先进的诊断和治疗，从而快速康复。医疗支出由自付费用（患者自费治疗）、政府支出以及医疗保险和非政府组织（NGO）的活动等来源组成。由于癌症治疗医疗支出的增加，这为市场增长提供了机会。
挑战
癌症诊断产品审批和商业化的严格监管框架
任何产品在市场上的审批和商业化都受到严格的监管，这是美国和欧洲地区癌症诊断产品制造商面临的主要挑战之一。每个国家都有自己的法规，并且监管程序也由不同的机构负责。
潜在的监管途径对于美国食品药品管理局 (FDA) 批准、认可或接受复杂特征是必不可少的。监管途径包括适用于体外诊断 (IVD) 设备的法规，包括伴随诊断设备、标记为补充诊断的可能性以及生物标志物资格认证计划。
最新动态
- 2022 年 8 月，罗氏公司宣布推出数字 LightCycler 系统，这是罗氏的首款数字聚合酶链反应 (PCR) 系统。这款新一代系统可检测疾病，旨在准确量化传统 PCR 方法通常无法检测到的特定 DNA 和 RNA 靶标的微量。这有助于该公司扩大其在北美市场的影响力
- 2022 年 5 月，全球科学服务领导者赛默飞世尔科技公司 (Thermo Scientific Inc.) 推出了 Thermo Scientific Glacios 2 低温透射电子显微镜 (Cryo-TEM)，这是一款功能强大的显微镜，具有新的自动化和高分辨率成像功能，旨在帮助不同经验水平的低温电子显微镜 (cryo-EM) 研究人员加速基于结构的药物发现。这种先进、快速且经济高效的药物设计方法可能使客户能够加快对阿尔茨海默病、帕金森病和亨廷顿病等衰弱性疾病以及癌症和基因突变的研究速度
北美甲状腺癌诊断市场范围
北美甲状腺癌诊断市场细分为产品类型、检测类型、癌症类型、阶段、年龄组、最终用户和分销渠道。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，以便做出战略决策，确定核心市场应用。
产品类型
- 仪器
- 耗材及配件
根据产品类型，北美甲状腺癌诊断市场分为仪器和消耗品及配件。
测试类型
- 影像检查
- 验血
- 活检
- 其他的
根据测试类型，北美甲状腺癌诊断市场分为影像测试、血液测试、活检和其他。
癌症类型
- 乳头状癌
- 滤泡性癌
- 其他的
根据癌症类型，北美甲状腺癌诊断市场分为乳头状癌、滤泡性癌和其他。
阶段
- 第一阶段
- 第二阶段
- 第三阶段
- 第四阶段
On the basis of stages, the North America thyroid cancer diagnostics market is segmented into stage I, stage II, stage III and stage IV.
Age Group
- 30-65
- 65 and above
- 21-29
- Below 21
On the basis of age group, the North America thyroid cancer diagnostics market is segmented into 30-65, 65 and above, 21-29, and below 21.
End User
- Hospitals
- Associated Labs
- Independent Diagnostic Laboratories
- Diagnostic Imaging Centers
- Cancer Research Institutes
- Others
On the basis of end user, the North America thyroid cancer diagnostics market is segmented into hospitals, associated labs, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.
Distribution Channel
- Direct Tender
- Retail Sales
On the basis of distribution channel, the North America thyroid cancer diagnostics market is segmented into direct tender and retail sales.
North America Thyroid Cancer Diagnostics Market Regional Analysis/Insights
The North America thyroid cancer diagnostics market is analysed, and market size insights and trends are provided by country, product type, test type, cancer type, stages, age group, end user, and distribution channel, as referenced above.
The countries covered in this market report are U.S., Canada, and Mexico.
The U.S. is expected to dominate the North America thyroid cancer diagnostics market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to rising thyroid cancer diagnostic tests.
The country section of the report also provides individual market-impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of North American brands and the challenges faced due to competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Thyroid Cancer Diagnostics Market Share Analysis
North America thyroid cancer diagnostics market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the North America thyroid cancer diagnostics market.
北美甲状腺癌诊断市场的一些主要参与者包括佳能公司、富士胶片控股株式会社、罗氏有限公司、Quest Diagnostics Incorporated、Illumina、荷兰皇家飞利浦公司、赛默飞世尔科技公司、西门子医疗有限公司、雅培、通用电气公司、BD、QIAGEN、DIASORIN SPA、默克集团、Hologic、Myriad Genetics Inc.、BIOMERIEUX、FONAR Corp.、美时医疗控股、PlexBio.、明方医疗系统有限公司、Medonica 有限公司、北京欧德生物技术有限公司和SternMed GmbH 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS
5 EPIDEMIOLOGY
6 REGULATORY FRAMEWORK OF THE NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET
6.1 REGULATORY SCENARIO IN THE U.S.
6.2 REGULATORY SCENARIO IN AUSTRALIA
6.3 REGULATORY SCENARIO IN JAPAN
6.4 REGULATORY SCENARIO IN CHINA
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING INCIDENCE AND PREVALENCE OF THYROID NODULES AND CANCER
7.1.2 RISING THYROID CANCER DIAGNOSTIC TESTS
7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS
7.1.4 RISING AWARENESS TOWARDS THYROID CANCER
7.2 RESTRAINTS
7.2.1 HIGH COST OF DIAGNOSTICS PROCEDURE
7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS
7.3 OPPORTUNITIES
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT
7.3.2 RISING OBESE POPULATION
7.4 CHALLENGES
7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS
7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE
8 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 INSTRUMENTS
8.2.1 PATHOLOGY BASED INSTRUMENTS
8.2.1.1 PCR INSTRUMENTS
8.2.1.2 SLIDE STAINING SYSTEMS
8.2.1.3 TISSUE PROCESSING SYSTEMS
8.2.1.4 CELL PROCESSORS
8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS
8.2.2 IMAGING INSTRUMENTS
8.2.2.1 ULTRASOUND SYSTEMS
8.2.2.2 CT SYSTEMS
8.2.2.3 MRI SYSTEMS
8.2.2.4 OTHERS
8.2.3 BIOPSY INSTRUMENTS
8.2.3.1 NEEDLE BIOPSY
8.2.3.2 ENDOSCOPIC BIOPSY
8.2.3.3 CORE BIOPSY
8.2.3.4 OTHERS
8.2.4 OTHERS
8.3 CONSUMABLES & ACCESSORIES
8.3.1 KITS
8.3.1.1 PCR KITS
8.3.1.2 DNA POLYMERASE KITS
8.3.1.3 NUCLEIC ACID ISOLATION KITS
8.3.1.4 OTHERS
8.3.2 REAGENTS
8.3.2.1 ASSAYS
8.3.2.2 BUFFERS
8.3.2.3 PRIMERS
8.3.2.4 OTHERS
8.3.3 PROBES
8.3.4 OTHER CONSUMABLES
9 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 IMAGING TEST
9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN
9.2.2 MRI
9.2.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN
9.2.4 OTHERS
9.3 BLOOD TEST
9.3.1 BLOOD CHEMISTRY TESTS
9.3.2 COMPLETE BLOOD COUNT (CBC)
9.3.3 OTHERS
9.4 BIOPSY
9.4.1 NEEDLE BIOPSY
9.4.2 BRONCHOSCOPY BIOPSY
9.4.3 CORE BIOPSY
9.4.4 OTHERS
9.5 OTHERS
10 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE
10.1 OVERVIEW
10.2 PAPILLARY CARCINOMA
10.3 FOLLICULAR CARCINOMA
10.4 OTHERS
11 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES
11.1 OVERVIEW
11.2 STAGE I
11.3 STAGE II
11.4 STAGE III
11.5 STAGE IV
12 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP
12.1 OVERVIEW
12.2 30-65
12.3 65 AND ABOVE
12.4 21-29
12.5 BELOW 21
13 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 ASSOCIATED LABS
13.4 INDEPENDENT DIAGNOSTIC LABORATORIES
13.5 DIAGNOSTIC IMAGING CENTERS
13.6 CANCER RESEARCH INSTITUTES
13.7 OTHERS
14 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDER
14.3 RETAIL SALES
15 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY REGION
15.1 NORTH AMERICA
15.1.1 U.S.
15.1.2 CANADA
15.1.3 MEXICO
16 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 CANON INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 COMPANY SHARE ANALYSIS
18.1.3 PRODUCT PORTFOLIO
18.1.4 RECENT DEVELOPMENTS
18.2 FUJIFILM CORPORATION
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENT
18.3 F. HOFFMANN-LA ROCHE LTD
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 QUEST DIAGNOSTICS INCORPORATED
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 ILLUMINA, INC.
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENT
18.6 ABBOTT
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENT
18.7 BD
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENT
18.8 BEIJING O&D BIOTECH CO., LTD.
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENTS
18.9 BIOMÉRIEUX SA
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENTS
18.1 DIASORIN S.P.A.
18.10.1 COMPANY SNAPSHOT
18.10.2 REVENUE ANALYSIS
18.10.3 PRODUCT PORTFOLIO
18.10.4 RECENT DEVELOPMENT
18.11 FONAR CORP.
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENTS
18.12 GENERAL ELECTRIC
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENTS
18.13 HOLOGIC INC.
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENT
18.14 KONINKLIJKE PHILIPS N.V.
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENT
18.15 MERCK KGAA.
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENT
18.16 MEDONICA CO. LTD
18.16.1 COMPANY SNAPSHOT
18.16.2 PRODUCT PORTFOLIO
18.16.3 RECENT DEVELOPMENT
18.17 MINFOUND MEDICAL SYSTEMS CO. LTD
18.17.1 COMPANY SNAPSHOT
18.17.2 PRODUCT PORTFOLIO
18.17.3 RECENT DEVELOPMENTS
18.18 MYRIAD GENETICS, INC.
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENTS
18.19 PLEXBIO.
18.19.1 COMPANY SNAPSHOT
18.19.2 PRODUCT PORTFOLIO
18.19.3 RECENT DEVELOPMENTS
18.2 QIAGEN
18.20.1 COMPANY SNAPSHOT
18.20.2 REVENUE ANALYSIS
18.20.3 PRODUCT PORTFOLIO
18.20.4 RECENT DEVELOPMENT
18.21 STERNMED GMBH
18.21.1 COMPANY SNAPSHOT
18.21.2 PRODUCT PORTFOLIO
18.21.3 RECENT DEVELOPMENTS
18.22 SIEMENS HEALTHCARE GMBH
18.22.1 COMPANY SNAPSHOT
18.22.2 REVENUE ANALYSIS
18.22.3 PRODUCT PORTFOLIO
18.22.4 RECENT DEVELOPMENT
18.23 TIME MEDICAL HOLDING.
18.23.1 COMPANY SNAPSHOT
18.23.2 PRODUCT PORTFOLIO
18.23.3 RECENT DEVELOPMENT
18.24 THERMO FISHER SCIENTIFIC INC.
18.24.1 COMPANY SNAPSHOT
18.24.2 REVENUE ANALYSIS
18.24.3 PRODUCT PORTFOLIO
18.24.4 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 2 NORTH AMERICA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 NORTH AMERICA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA OTHERS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA PAPILLARY CARCINOMA IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA FOLLICULAR CARCINOMA IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA OTHERS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA STAGE I IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA STAGE II IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA STAGE III IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA STAGE IV IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA 30-65 IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA 65 AND ABOVE IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA 21-29 IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA BELOW 21 IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA HOSPITALS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA ASSOCIATED LABS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 NORTH AMERICA INDEPENDENT DIAGNOSTIC LABORATORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA DIAGNOSTIC IMAGING CENTERS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 NORTH AMERICA CANCER RESEARCH INSTITUTES IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA OTHERS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 41 NORTH AMERICA DIRECT TENDER IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 NORTH AMERICA RETAIL SALES IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 44 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 45 NORTH AMERICA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 46 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 47 NORTH AMERICA IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 48 NORTH AMERICA BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 50 NORTH AMERICA KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 51 NORTH AMERICA REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 52 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 53 NORTH AMERICA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 54 NORTH AMERICA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 55 NORTH AMERICA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 56 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 57 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 58 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 59 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 60 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 61 U.S. THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 62 U.S. INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 63 U.S. PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 64 U.S. IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 65 U.S. BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 66 U.S. CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 67 U.S. KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 68 U.S. REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 69 U.S. THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 70 U.S. IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 71 U.S. BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 72 U.S. BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 73 U.S. THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 74 U.S. THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 75 U.S. THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 76 U.S. THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 77 U.S. THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 78 CANADA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 79 CANADA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 80 CANADA PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 81 CANADA IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 82 CANADA BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 83 CANADA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 84 CANADA KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 85 CANADA REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 86 CANADA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 87 CANADA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 88 CANADA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 89 CANADA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 90 CANADA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 91 CANADA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 92 CANADA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 93 CANADA THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 94 CANADA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 95 MEXICO THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 96 MEXICO INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 97 MEXICO PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 98 MEXICO IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 99 MEXICO BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 100 MEXICO CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 101 MEXICO KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 102 MEXICO REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 103 MEXICO THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 104 MEXICO IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 105 MEXICO BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 106 MEXICO BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 107 MEXICO THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 108 MEXICO THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 109 MEXICO THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 110 MEXICO THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 111 MEXICO THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 9 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT THYROID CANCER IS EXPECTED TO DRIVE THE NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD
FIGURE 12 PRODUCT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET
FIGURE 14 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 15 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 16 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 17 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 19 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 20 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 21 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022
FIGURE 23 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 24 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 25 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 26 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY STAGES, 2022
FIGURE 27 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY STAGES, 2023-2030 (USD MILLION)
FIGURE 28 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY STAGES, CAGR (2023-2030)
FIGURE 29 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY STAGES, LIFELINE CURVE
FIGURE 30 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022
FIGURE 31 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 32 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 33 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 34 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 35 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 36 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 37 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 39 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 40 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 41 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 43 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 44 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 45 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 46 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030)
FIGURE 47 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
